Download Ching-Hung Lin (Taiwan)

CURRICULUM VITAE
Name: Ching-Hung Lin, 林璟宏
Institute: Department of Oncology, National Taiwan University Hospital
Address: 7 Chung-Shan South Road, Taipei 100
Tel: 886-2-2312-3456 Ext 67513
E-Mail: [email protected]
EDUCATION
1991.9- 1997-6
2003.9-2005.6
2005.9- 2011.12
M.D. Department of Medicine, College of Medicine,
National Taiwan University
M.S. Graduate Institute of Clinical Medicine, College of
Medicine, National Taiwan University
Ph.D. Graduate Institute of Clinical Medicine, College of
Medicine, National Taiwan University
POSTDOCTORAL TRAINING
1999.7- 2002.6
Residency training, Department of Internal Medicine,
National Taiwan University Hospital
2002.7- 2003.6
Chief Resident, Department of Oncology, National
2003.7- 2004.6
2004.7- 2005.6
Taiwan University Hospital
Fellowship training of oncology, Department of Oncology,
National Taiwan University Hospital
Fellowship training of hematology, Department of Internal
Medicine, National Taiwan University Hospital
LICENSURE AND CERTIFICATION
1997
National Medical Board of Republic of China
2002
Specialist of Internal Medicine, R.O.C
2004
Specialist of Medical Oncology, R.O.C
2005
Specialist of Hematology, R.O.C
HOSPITAL APPOINTMENTS
2005- present
Attending Physician, Department of Oncology, National
Taiwan University Hospital
2012- present
Assistant Professor, Department of Internal Medicine,
National Taiwan University Hospital
PUBLICATIONS
(* corresponding author)
1. Lin CH, Yen RF, Jeng YM, Tzen CY, Hsu C, Hong RL Imatinib Mesylate in
the Treatment of Metastatic Adenoid Cystic Carcinoma. Head & Neck
2005 Dec;27(12):1022-7
2. Lin CH, Kuo KT, Chuang SS, Kuo SH, Chang JH, Chang KC, Hsu HC,
Tien HF, Cheng AL. Comparison of Expression and Prognostic
Significance of Differentiation Makers of Diffuse Large B-Cell lymphoma of
Central Nervous System Origin or Peripheral Nodal Origin. Clin Cancer
Res 2006 Feb; 12: 1152-1156
3.
4.
5.
6.
7.
Kuo KT, Liang CW, Hsiao CH, Lin CH, Chen CA, Sheu BC, Lin MC.
Downregulation of BRG-1 repressed expression of CD44s in cervical
neuroendocrine carcinoma and adenocarcinoma. Mod Pathol. 2006
Dec;19(12):1570-7.
Hong RL, Lin CH, Chao TY, Kao WY, Wang CH, Hsieh RK, Hwang WS. A
phase I study evaluating the combination of pegylated liposomal
doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast
cancer previously treated with anthracycline. Cancer Chemother and
Pharmacol. 2008 Apr;61(5):847-53.
Kuo KT, Hsiao CH, Lin CH, Kuo LT, Huang SH, Lin MC. The biomarkers
of human papillomavirus infection in tonsillar squamous cell
carcinoma-molecular basis and predicting favorable outcome. Mod Pathol.
2008 Apr;21(4):376-86
Kuo SH, Lien HC, You SL, Lu YS, Lin CH, Chen TZ, Huang CS. Dose
variation and regimen modification of adjuvant chemotherapy in daily
practice affect survival of stage I-II and operable stage III Taiwanese
breast cancer patients. Breast. 2008 Dec;17(6):646-53. Jun 30.
Huang CS, Kuo SH, Lien HC, Yang SY, You SL, Shen CY, Lin CH, Lu YS,
Chang KJ. The CYP19 TTTA Repeat Polymorphism Is Related to the
Prognosis of Premenopausal Stage I–II and Operable Stage III Breast
8.
9.
Cancers. The Oncologist 2008 Jul;13(7):751-60.
Lin HJ, Zuo T, Lin CH, Kuo CT, Liyanarachchi S, Sun S, Shen R,
Deatherage DE, Potter D, Asamoto L, Lin S, Yan PS, Cheng AL,
Ostrowski MC, Huang TH. Breast cancer-associated fibroblasts confer
AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells.
Cancer Res. 2008 Dec 15;68(24):10257-66
Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, Shen YC, Kuo SH,
Lan C, Liu J. M, Kuo WH, Chang KJ, Cheng AL. Molecular Subtypes of
Breast Cancer Emerging in Young Women in Taiwan: Evidence for More
than Just Westernization as a Reason for the Disease in Asia. Cancer
Epidemiol Biomarkers Prev. 2009 Jun;18(6):1807-14.
10. Chang DY, Lin CH, Lu YS. Locoregional therapy improves survial for
metastatic breast cancer patiets? Benefit remains questionable! J Clin
Oncol. 2009 Nov 1;27(31):e179
11. Wu PF, Kuo KT, Kuo LT, Lin YT, Lee WC, Lu YS, Yang CH, Wu RM, Tu
YK, Tsai JC, Tseng HM, Tseng SH, Cheng AL, Lin CH*
O6-methylguanine-DNA methyltransferase expression and prognostic
value in brain metastases of lung cancers. Lung Cancer 2010
Jun;68(3):484-90. (*corresponding author)
12. Lin CH, Lien HC, Hu FC, Lu YS, Kuo SH, Wu LC, You SL, Cheng AL,
Chang KJ, Huang CS. Fractionated evaluation of immunohistochemical
hormone receptor expression enhances prognostic prediction in breast
cancer patients treated with tamoxifen as adjuvant therapy. J Zhejiang
Univ Sci B. 2010 Jan;11(1):1-9.
13. Huang CS, Lin CH, Lu YS, Shen CY. Unique Features of Breast Cancer in
Asian Women - Breast Cancer in Taiwan as an Example. J Steroid
Biochem Mol Biol. 2010 Feb 28;118(4-5):300-3.
14. Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C,
Kuo WH, Chang KJ, Lin CH*, Cheng AL. Predictive and Prognostic Values
of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with
Paclitaxel and Cisplatin. Jpn J Clin Oncol. 2010 Apr;40(4):286-93.
(*corresponding author)
15. Weng YI, Hsu PY, Liyanarachchi S, Liu J, Deatherage DE, Huang YW,
Zuo T, Rodriguez B, Lin CH, Cheng AL, Huang TH. Epigenetic influences
of low-dose bisphenol A in primary human breast epithelial cells. Toxicol
Appl Pharmacol. 2010 Oct 15;248(2):111-21.
16. Lin PH, Lu YS, Lin CH, Chang DY, Huang CS, Cheng AL, Yeh KH.
Vinorelbine plus 24-Hour Infusion of High-dose 5-Fluorouracil and
Leucovorin as Effective Palliative Chemotherapy for Breast Cancer
Patients with Acute Disseminated Intravascular Coagulation. Anticancer
Res. 2010 Jul;30(7):3087-91.
17. Wang J, Shih TT, Yen RF, Lu YS, Chen CY, Mao TL, Lin CH, Kuo WH,
Tsai YS, Chang KJ, Chien KL. The Association of Infrared Imaging
Findings of the Breast with Hormone Receptor and Human Epidermal
Growth Factor Receptor 2 Status of Breast Cancer. Acad Radiol. 2011
Feb;18(2):212-9.
18. Chen CL, Chen KC, Pan YC, Lee TP, Hsiung LC, Lin CM, Chen CY, Lin
CH, Chiang BL, Wo AM. Separation and detection of rare cells in a
microfluidic disk via negative selection. Lab Chip. 2011 Feb
7;11(3):474-83.
19. Rodriguez BA, Weng YI, Liu TM, Zuo T, Hsu PY, Lin CH, Cheng AL, Cui H,
Yan PS, Huang TH. Estrogen-Mediated Epigenetic Repression of the
Imprinted Gene Cyclin Dependent Kinase Inhibitor 1C in Breast Cancer
Cells. Carcinogenesis 2011 Jun;32(6):812-21.
20. Kuo SH, Hsu CH, Chen LT, Lu YS, Lin CH, Yeh PY, Jeng HJ, Gao M, Yeh
KH, Cheng AL. Lack of compensatory pAKT activation and eIF4E
phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001. Eur
J Cancer. 2011 May;47(8):1244-57.
21. Hsiung LC, Chiang CL, Wang CH, Huang YH, Kuo CT, Cheng JY, Lin CH,
Wu V, Chou HY, Jong DS, Lee H, Wo AM. Dielectrophoresis-based
cellular microarray chip for anticancer drug screening in perfusion
microenvironments. Lab Chip. 2011 Jul 21; 11 (14), 2333 - 2342
22. Chen IC, Lin CH, Lu YS. Axillary vs Sentinel Lymph Node Dissection for
Invasive Breast Cancer. JAMA. 2011 Jun 8;305(22):2288-9.
23. Lin CH, Lu YS, Huang CS, Kuo KT, Wang CC, You SL, Lin PH, Chang
DW, Kuo WH, Chang KJ, Cheng AL. Prognostic molecular markers in
women aged 35 years or younger with breast cancer– Is there a difference
from the older patients? J Clin Pathol. 2011 Sep;64(9):781-7.
24. Chen IC, Lin CH, Huang CS, Lien HC, HsuC, Kuo WH, Lu YS, and Cheng
AL. Lack of efficacy to systemic chemotherapy for treatment of metaplastic
carcinoma of the breast in the modern era. Breast Cancer Res Treat. 2011
Nov;130(1):345-51.
25. Kuo WH, Lin PH, Huang AC, Chien YH, Liu TP, Lu YS, Bai LY, Sargeant
AM, Lin CH, Cheng AL, Hsieh FJ, Hwu WL, Chang KJ. Multimodel
assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women
with early-onset, bilateral or familial breast cancer. J Hum Genet. 2012
Feb;57(2):130-8.
26. Lin YC, Chen KC, Lin CH, Kuo KT, Ko JY, Hong RL. Clinicopathological
features of salivary and non-salivary adenoid cystic carcinomas. Int J Oral
Maxillofac Surg. 2012 Mar;41(3):354-60.
27. Lin CH, Chen YC, Chiang CL, Lu YS, Kuo KT, Huang CS, Cheng WF, Lai
MS, You SL, Cheng AL. The emerging epidemic of estrogen-related
cancers in young women in a developing Asian country. Int J Cancer. 2012
Jun 1;130(11):2629-37.
28. Chen KC, Pan YC, Chen CL, Lin CH, Huang CS, Wo AM. Enumeration
and viability of rare cells in a microfluidic disk via positive selection
approach. Anal Biochem. 2012 Oct 15;429(2):116-23.
29. Liang YH, Wu PF, Lin CH, Lu YS. Hashimoto's Encephalopathy As the
Cause of Deteriorating Consciousness During Treatment of
Leptomeningeal Carcinomatosis From Breast Cancer. J Clin Oncol. 2012
Nov 20;30(33):e358-9.
30. Kuo YH, Lin CH, Shau WY, Chen TJ, Yang SH, Huang SM, Hsu C, Lu YS,
Cheng AL. Dynamics of circulating endothelial cells and endothelial
progenitor cells in breast cancer patients receiving cytotoxic
chemotherapy.BMC Cancer. 2012 Dec 26;12(1):620. doi: 10.1186/
1471-2407-12-620
31. Lin CH, Liu JM, Lu YS, Lan C, Lee WC, Kuo KT, Wang CC, Chang DY,
Huang CS, Cheng AL. Clinical significance of ESR1 gene copy number
changes in breast cancer as measured by fluorescence in situ
hybridisation. J Clin Pathol. 2013 Feb;66(2):140-5.
32. Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, Li H, Lin YC,
Chang HK, Chao TC, Ouyang F, Hou MF. Distant metastasis in
triple-negative breast cancer. Neoplasma. 2013;60(3):290-4.
33. Lien HC, Wang CC, Lin CH, Lu YS, Huang CS, Hsiao LP, Yao YT.
Differential expression of ubiquitin carboxy-terminal hydrolase L1 in breast
carcinoma and its biological significance. Hum Pathol. 2013
Sep;44(9):1838-48.
34. Wu PF, Huang WC, Yang JC, Lu YS, Shih JY, Wu SG, Lin CH*, Cheng AL.
Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor
prognostic factor in brain metastases from lung adenocarcinomas. J
Neurooncol. 2013 Oct;115(1):61-70. (*corresponding author)
35. Chen WW, Chang DY, Huang SM, Lin CH, Hsu C, Lin MH, Huang CS, Lu
YS, Cheng AL. The first two lines of chemotherapy for anthracycline-naive
metastatic breast cancer: A comparative study of the efficacy of
anthracyclines and non-anthracyclines. Breast. 2013 Dec;22(6):1148-54.
36. Kuo SH, Yang SY, Lien HC, Lo C, Lin CH, Lu YS, Cheng AL, Chang KJ,
Huang CS. CYP19 genetic polymorphism haplotype AASA is associated
with a poor prognosis in premenopausal women with lymph node-negative,
hormone receptor-positive breast cancer. Biomed Res Int. 2013;
2013:562197. doi: 10.1155/2013/562197.
37. Lien HC, Lee YH, Jeng YM, Lin CH, Lu YS, Yao YT. Differential
expression of hyaluronan synthase 2 in breast carcinoma and its biological
significance. Histopathology. 2014 Sep;65(3):328-39.
38. Lin CH, Chuang PY, Chiang CL, Lu YS, Cheng AL, Kuo WH, Huang CS,
Lai MS, You SL, Tang CH. Distinct Clinicopathological Features and
Prognosis of Emerging Young Female Breast Cancer in an East Asian
Country: a Nationwide Cancer Registry-based Study. The Oncologist 2014
Jun;19(6):583-91.
39. Liao HW, Tsai IL, Chen GY, Lu YS, Lin CH, Kuo CH. Quantification of
target analytes in various biofluids using a postcolumn infused-internal
standard method combined with matrix normalization factors in liquid
chromatography-electrospray ionization mass spectrometry. J Chromatogr
A. 2014 Jun 30. pii: S0021-9673(14)01012-7.
40. Kuo CT, Liu HK, Huang GS, Chang CH, Chen CL, Chen KC, Yun-Ju
Huang R, Lin CH, Lee H, Huang CS, Wo AM. A spatiotemporally defined
in vitro microenvironment for controllable signal delivery and drug
screening. Analyst. 2014 Oct 7;139(19):4846-54.
41. Huang HN, Huang WC, Lin CH, Chiang YC, Huang HY, Kuo KT.
Chromosome 20q13.2 ZNF217 locus amplification correlates with
decreased E-cadherin expression in ovarian clear cell carcinoma with
PI3K-Akt pathway alterations. Hum Pathol. 2014 Nov;45(11):2318-25.
42. Chen TW, Chen HM, Lin CH, Huang CS, Cheng AL, Lai MS, Lu YS. No
increased venous thromboembolism risk in Asian breast cancer patients
receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2014
Nov;148(1):135-42.
43. Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, Rau KM, Chen BB,
Chao TC, Huang SM, Huang CS, Shih TT, Cheng AL. Bevacizumab
Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in
Treating Brain Metastases of Breast Cancer Progressing from
Whole-Brain Radiotherapy. Clin Cancer Res. 2015 Apr 15;21(8):1851-8.
44. Ma WY, Hsiung LC, Wang CH, Chiang CL, Lin CH, Huang CS, Wo AM. A
Novel 96well-formatted Micro-gap Plate Enabling Drug Response Profiling
on Primary Tumour Samples. Sci Rep. 2015 Apr 13;5:9656. doi:
10.1038/srep09656.
45. Lin CH, Shen CY, Lee JH, Huang CS, Yang CH, Kuo WH, Chang DW,
Hsiung CN, Kuo KT, Chen WW, Chen IC, Wu PF, Kuo SH, Chen CJ, Lu
YS, Cheng AL. High Prevalence of the BIM Deletion Polymorphism in
Young Female Breast Cancer in an East Asian Country. PLoS One. 2015
Apr 24;10(4):e0124908. doi: 10.1371/journal.pone.0124908.
46. Chang C, Lin CH, Cheng AL, Chang KC. Primary Central Nervous System
Diffuse Large B-cell Lymphoma Has Poorer Immune Cell Infiltration and
Prognosis than Peripheral Counterpart. Histopathology 2015 [Epub ahead
of print]
47. Chen IC, Lin CH, Jan IS, Cheng AL, Lu YS. Bevacizumab might potentiate
the chemotherapeutic effect in breast cancer patients with leptomeningeal
carcinomatosis. J Formos Med Assoc. 2015 Apr 15. pii:
S0929-6646(15)00133-3. doi: 10.1016/j.jfma.2015.03.005. [Epub ahead of
print]
48. Wu PF, Lin CH, Kuo CH, Chen WW, Yeh DC, Liao HW, Huang SM,
Cheng AL, Lu YS. A pilot study of bevacizumab combined with etoposide
and cisplatin in breast cancer patients with leptomeningeal carcinomatosis.
BMC Cancer. 2015 Apr 17;15(1):299. doi: 10.1186/ s12885-015-1290-1.